Consolidated Statements of Shareholders’ Equity (Deficit) - USD ($) $ in Thousands	Total	Common Shares	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Public Offering	Public Offering Common Shares	Public Offering Additional Paid-in Capital	Roivant Sciences, Ltd. Private Placement	Roivant Sciences, Ltd. Private Placement Common Shares	Roivant Sciences, Ltd. Private Placement Additional Paid-in Capital	Cowen and Company, LLC Private Placement	Cowen and Company, LLC Private Placement Common Shares	Cowen and Company, LLC Private Placement Additional Paid-in Capital
Opening balance at Mar. 31, 2018	$ 71,286	$ 0	$ 628,111	$ (556,951)	$ 126
Opening balance (in shares) at Mar. 31, 2018		13,473,512
Increase (Decrease) in Shareholders' Equity (Deficit)
Issuance of shares upon exercise of stock options	$ 335		335
Issuance of shares upon exercise of stock options (in shares)	39,130	39,130
Stock issued						$ 69,488		$ 69,488	$ 25,000		$ 25,000	$ 61		$ 61
Stock issued (in shares)							7,478,448			1,785,714			3,087
Share-based compensation expense	$ 19,067		19,067
Capital contribution — share-based compensation expense	(2,638)		(2,638)
Non-cash capital contribution received from Roivant Sciences, Inc.	1,894		1,894
Foreign currency translation adjustment	785				785
Net loss	(129,065)			(129,065)
Ending balance at Mar. 31, 2019	56,213	$ 0	741,318	(686,016)	911
Ending balance (in shares) at Mar. 31, 2019		22,779,891
Increase (Decrease) in Shareholders' Equity (Deficit)
Issuance of shares upon exercise of stock options	$ 86		86
Issuance of shares upon exercise of stock options (in shares)	11,778	11,778
Shares issued for restricted stock units (in shares)		103,294
Shares issued for restricted stock units	$ 0
Stock issued						$ 70,810		$ 70,810
Stock issued (in shares)							16,631,336
Share-based compensation expense	7,895		7,895
Non-cash capital contribution received from Roivant Sciences, Inc.	148		148
Foreign currency translation adjustment	(966)				(966)
Net loss	(72,628)			(72,628)
Ending balance at Mar. 31, 2020	$ 61,558	$ 0	$ 820,257	$ (758,644)	$ (55)
Ending balance (in shares) at Mar. 31, 2020		39,526,299